Статус неизвестен
Фаза II
Россия
Maxy-G34 · Maxygen Holdings Ltd.
A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer.